Last 12 months
Inside the activity.
0 purchase rows · 39 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 21 |
| Apr 2026 | 0 | 7 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2018 Filed Apr 9, 2018 20:09 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-024317 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2018 Filed Aug 10, 2018 21:17 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-046264 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · derivative · entry 9 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 2,113 | $79.49 | $167,962.37 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.16 to $80.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 3,390 | $78.59 | $266,420.10 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 5 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,113 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.11 to $79.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 3,340 | $77.76 | $259,718.40 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 4 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,503 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $77.10 to $78.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 2,600 | $76.40 | $198,640.00 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,843 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.02 to $77.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 1,557 | $75.54 | $117,615.78 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,443 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $75.00 to $75.89. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:03 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-023581 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 4,100 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · derivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,718 Underlying: Common stock · 4,100 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 37 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · derivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766 Underlying: Common stock · 37 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 4,100 | $2.34 | $9,594.00 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2018 Filed Mar 30, 2018 20:18 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 37 | $0.47 | $17.30 |
DisclosureSEC source: 0001209191-18-022211 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2018 Filed Aug 10, 2018 21:16 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 4,100 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001209191-18-046262 · doc4a.xml · derivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,718 Underlying: Common stock · 4,100 shares Expires 2022-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F3 · derivative.exercise_date: This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares, and the remaining 15,909 shares vested on April 4, 2015. Read SEC document |
| March 28, 2018 Filed Aug 10, 2018 21:16 UTC Amendment |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 37 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-18-046262 · doc4a.xml · derivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766 Underlying: Common stock · 37 shares Expires 2020-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The original Form 4 stated that derivative securities were acquired as a result of the transaction, when in fact the transaction was a disposition of derivative securities. This Form 4 amendment is solely to correct the nature of the transaction. F2 · derivative.exercise_date: This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,900 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 2,050 | $84.65 | $173,532.50 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 20:01 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-021611 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 6,800 | $0.00 Strike: $47.33 | $0.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · derivative · entry 3 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,800 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC |
Foster-Cheek Kaye IDirector
|
SaleCommon stock | 6,800 | $81.97 | $557,396.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · nonDerivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:04 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionCommon stock | 6,800 | $47.33 | $321,844.00 |
DisclosureSEC source: 0001209191-18-021060 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 20:43 UTC |
Scadden DavidDirector
|
PurchaseCommon stock | 200 | $83.44 | $16,688.00 |
DisclosureSEC source: 0001209191-18-020896 · doc4.xml · nonDerivative · entry 1 Scadden David · CIK 0001707715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571 Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:50 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.16 | $0.00 |
DisclosureSEC source: 0001209191-18-020231 · doc4.xml · derivative · entry 4 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,000 Underlying: Common stock · 2,000 shares Expires 2024-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:50 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 300 | $82.90 | $24,870.00 |
DisclosureSEC source: 0001209191-18-020231 · doc4.xml · nonDerivative · entry 3 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.82 to $83.09. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:50 UTC |
Bowden ChristopherChief Medical Officer
|
SaleCommon stock | 1,700 | $82.23 | $139,791.00 |
DisclosureSEC source: 0001209191-18-020231 · doc4.xml · nonDerivative · entry 2 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.78 to $82.77. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 20:50 UTC |
Bowden ChristopherChief Medical Officer
|
Exercise / conversionCommon stock | 2,000 | $35.16 | $70,320.00 |
DisclosureSEC source: 0001209191-18-020231 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionStock options (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · derivative · entry 6 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,154 Underlying: Common stock · 3,000 shares Expires 2023-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 1,100 | $84.10 | $92,510.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 5 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,059 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $83.66 to $84.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 1,100 | $83.21 | $91,531.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 4 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,159 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $82.65 to $83.57. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 400 | $82.04 | $32,816.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 3 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,259 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $81.53 to $82.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
SaleCommon stock | 400 | $80.93 | $32,372.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 2 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,659 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.49 to $81.35. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC |
Biller ScottChief Scientific Officer
|
Exercise / conversionCommon stock | 3,000 | $9.05 | $27,150.00 |
DisclosureSEC source: 0001209191-18-017686 · doc4.xml · nonDerivative · entry 1 Biller Scott · CIK 0001581956 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · derivative · entry 6 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,567 Underlying: Common stock · 13,000 shares Expires 2019-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option was granted on August 13, 2009. The option vested as to 50% of the underlying shares upon the achievement of a performance milestone, as determined by the issuer's Board of Directors on June 3, 2010, and as to the remaining 50% of the underlying shares in equal monthly installments through June 3, 2013. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 10,085 | $81.30 | $819,910.50 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 3 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $80.80 to $81.77. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC |
Schenkein David PDirector · Chief Executive Officer
|
SaleCommon stock | 2,915 | $80.38 | $234,307.70 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 2 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,085 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $79.80 to $80.79. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:32 UTC |
Schenkein David PDirector · Chief Executive Officer
|
Exercise / conversionCommon stock | 13,000 | $0.30 | $3,932.50 |
DisclosureSEC source: 0001209191-18-016471 · doc4.xml · nonDerivative · entry 1 Schenkein David P · CIK 0001578200 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:02 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 2,200 | $0.00 Strike: $47.33 | $0.00 |
DisclosureSEC source: 0001209191-18-014455 · doc4.xml · derivative · entry 2 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common stock · 2,200 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:02 UTC |
Foster-Cheek Kaye IDirector
|
Exercise / conversionCommon stock | 2,200 | $47.33 | $104,126.00 |
DisclosureSEC source: 0001209191-18-014455 · doc4.xml · nonDerivative · entry 1 Foster-Cheek Kaye I · CIK 0001312622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,050 | $0.00 Strike: $39.76 | $0.00 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · derivative · entry 3 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,950 Underlying: Common stock · 2,050 shares Expires 2026-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC |
Hoerter Steven L.Chief Commercial Officer
|
SaleCommon stock | 2,050 | $78.63 | $161,191.50 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · nonDerivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:45 UTC |
Hoerter Steven L.Chief Commercial Officer
|
Exercise / conversionCommon stock | 2,050 | $39.76 | $81,508.00 |
DisclosureSEC source: 0001209191-18-013400 · doc4.xml · nonDerivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 16:05 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantRestricted stock units · Derivative | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011251 · doc4.xml · derivative · entry 3 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Underlying: Common stock · 2,370 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16,2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 16:05 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantRestricted stock units · Derivative | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011251 · doc4.xml · derivative · entry 2 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common stock · 2,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: All of the restricted stock units will vest on February 16, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 16:05 UTC |
Alenson CarmanPrincipal Accounting Officer
|
GrantStock option (right to buy) · Derivative | 9,480 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011251 · doc4.xml · derivative · entry 1 Alenson Carman · CIK 0001688865 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,480 Underlying: Common stock · 9,480 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:04 UTC |
Hoerter Steven L.Chief Commercial Officer
|
GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011249 · doc4.xml · derivative · entry 2 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:04 UTC |
Hoerter Steven L.Chief Commercial Officer
|
GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011249 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Hirsch AndrewChief Financial Officer
|
GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011246 · doc4.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Hirsch AndrewChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011246 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · derivative · entry 6 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F8 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC |
Bowden ChristopherChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011244 · doc4.xml · derivative · entry 5 Bowden Christopher · CIK 0001608601 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F6 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.